Percutaneous left ventricular assist devices are approved for cardiogenic shock, but there has been increasing interest in utilizing these devices for hemodynamic support as bridge to durable mechanical circulatory support (MCS). A 63 year-old male with severe ischemic cardiomyopathy was evaluated for MCS. Given severe MR at baseline, it was felt that the Impella 5. 
Introduction
Percutaneous left ventricular assist devices are increasingly being considered as a bridge to durable therapy in the setting of decompensated heart failure. The Impella 5.0 (ABIOMED, Inc., Danvers, MA) has recently been introduced, and two main scenarios are emerging for its use in advanced heart failure: (i) refractory cardiogenic shock, for which the Impella carries an FDA indication, and (ii) optimization prior to durable mechanical circulatory support (MCS) or heart transplant, although evidence of benefit in the latter scenario is lacking [1] . We demonstrate the acute hemodynamic effects of Impella 5.0 ventricular unloading in a patient with severe ischemic cardiomyopathy and mitral regurgitation (MR) prior to left ventricular assist device (LVAD) implantation.
Case Presentation
A 63 year-old male with ischemic cardiomyopathy and NYHA class IV symptoms despite optimal medical therapy was evaluated at our institution. A recent right heart catheterization documented pulmonary vascular resistance of 4.5 Woods units and transpulmonary gradient of 21 mmHg, raising concern about listing for transplantation. The use of percutaneous MCS devices for this indication is expanding [2] . While the Impella 5.0 is indicated for refractory cardiogenic shock, [1, 3] there has been increasing use of this device as bridge to LVAD [4] . Future studies should examine the short-term effects of unloading with this device in relation to outcomes after definitive therapy is instituted.
